Is cancer vaccination feasible at older age?

Claudia Gravekamp, Arthee Jahangir

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Age-related defects of the immune system are responsible for T cell unresponsiveness to cancer vaccination at older age. Major immune defects at older age are lack of naive T cells, impaired activation pathways of T cells and antigen-presenting cells (APCs), and age-related changes in the tumor microenvironment (TME). This raises the question whether cancer vaccination is feasible at older age. We compared various cancer vaccine studies at young and old age, thereby focusing on the importance of both innate and adaptive immune responses for cancer immunotherapy. These analyses suggest that creating an immune-stimulating environment with help of the innate immune system may improve T cell responses in cancer vaccination at older age.

Original languageEnglish (US)
Pages (from-to)138-144
Number of pages7
JournalExperimental Gerontology
StatePublished - Jun 2014


  • Adaptive immune system
  • Aging
  • Cancer immunotherapy
  • Cancer vaccines
  • Immune system
  • Innate immune system

ASJC Scopus subject areas

  • Biochemistry
  • Aging
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Cell Biology


Dive into the research topics of 'Is cancer vaccination feasible at older age?'. Together they form a unique fingerprint.

Cite this